Effect of prior therapy on the clinical activity of imetelstat in patients with transfusion-dependent, ESA-relapsed or -refractory/-ineligible LR-MDS - Poll - MDSpire

Effect of prior therapy on the clinical activity of imetelstat in patients with transfusion-dependent, ESA-relapsed or -refractory/-ineligible LR-MDS

  • By

  • Rami S. Komrokji

  • Valeria Santini

  • Amer M. Zeidan

  • Mikkael A. Sekeres

  • Pierre Fenaux

  • Azra Raza

  • Moshe Mittelman

  • Sylvain Thépot

  • Rena Buckstein

  • Ulrich Germing

  • Yazan F. Madanat

  • María Díez-Campelo

  • David Valcárcel

  • Anna Jonášová

  • Souria Dougherty

  • Sheetal Shah

  • Qi Xia

  • Libo Sun

  • Shyamala Navada

  • Faye Feller

  • Michael R. Savona

  • Uwe Platzbecker

  • December 31, 2025

  • 0 min

Share

Original Source(s)

Effect of prior therapy on the clinical activity of imetelstat in patients with transfusion-dependent, ESA-relapsed or -refractory/-ineligible LR-MDS

  • by Rami S. Komrokji, Valeria Santini, Amer M. Zeidan, Mikkael A. Sekeres, Pierre Fenaux, Azra Raza, Moshe Mittelman, Sylvain Thépot, Rena Buckstein, Ulrich Germing, Yazan F. Madanat, María Díez-Campelo, David Valcárcel, Anna Jonášová, Souria Dougherty, Sheetal Shah, Qi Xia, Libo Sun, Shyamala Navada, Faye Feller, Michael R. Savona, Uwe Platzbecker

  • December 31, 2025

Related Content

The Role of Hemoglobin and Anemia in Preventing Dementia—Revisiting a Well-Known Protein

Real world outcomes of momelotinib in myelofibrosis patients with anemia: results from the MOMGEMFIN study

Plasma haem oxygenase-1 and interleukin-6 as adjunct host biomarkers associated with malaria